or Try an Advanced Search...

    Technical Analysis for LYRA - Lyra Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.30 7.30% 0.02
    LYRA closed up 7.3 percent on Monday, July 1, 2024, on 56 percent of normal volume.
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Very Strong Down Down Up
    Historical LYRA trend table...
    Date Alert Name Type % Chg
    Crossed Above 20 DMA Bullish 0.00%
    Wide Bands Range Expansion 0.00%
    Pocket Pivot Bullish Swing Setup 7.30%
    Wide Bands Range Expansion 7.30%
    Oversold Stochastic Weakness 7.30%
    Spinning Top Other 13.67%
    Narrow Range Bar Range Contraction 13.67%
    Wide Bands Range Expansion 13.67%
    Oversold Stochastic Weakness 13.67%
    Narrow Range Bar Range Contraction 11.20%
    Older End-of-Day Signals for LYRA ...

       Recent Intraday Alerts

    Alert Time
    Down 1% about 10 hours ago
    Up 1% about 10 hours ago
    Rose Above 10 DMA 3 days ago
    Up 3% 3 days ago
    Up 2% 3 days ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    LYRA Chart by TradingView
    Basic chart:

    Profile

    Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions using XTreo technology platform for the localized treatment of patients with ear, nose, and throat diseases. Its XTreo platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210 and LYR-220, which are bioresorbable polymeric matrices for the treatment of chronic rhinosinusitis. Lyra Therapeutics, Inc. was founded in 2005 and is headquartered in Watertown, Massachusetts.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Sinus Headache Chronic Rhinosinusitis Sinusitis

    Is LYRA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 4 bearish and 1 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 21 Lyra to cut 75% of workforce in portfolio shakeup
    May 21 Lyra Therapeutics Announces Cost-Cutting Measures to Preserve Capital
    May 7 Jefferies cuts Lyra to hold in wake of failed Phase 3 study
    May 7 Target upgraded, CVS downgraded: Wall Street's top analyst calls
    May 6 Lyra Therapeutics drops 92% as phase 3 rhinosinusitis asset fails
    May 6 Lyra Therapeutics Reports Topline Results from Phase 3 ENLIGHTEN 1 Trial for LYR-210 in Chronic Rhinosinusitis
    Apr 30 Lyra Therapeutics GAAP EPS of -$0.35 misses by $0.08, revenue of $0.53M beats by $0.18M
    Apr 30 Lyra Therapeutics, Inc. (LYRA) Reports Q1 Loss, Tops Revenue Estimates
    Apr 30 Lyra Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
    Apr 26 Lyra Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    See more LYRA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 6.79
    52 Week Low 0.2532
    Average Volume 4,637,055
    200-Day Moving Average 3.73
    50-Day Moving Average 1.35
    20-Day Moving Average 0.29
    10-Day Moving Average 0.27
    Average True Range 0.06
    RSI (14) 20.63
    ADX 59.98
    +DI 14.10
    -DI 43.69
    Chandelier Exit (Long, 3 ATRs) 0.16
    Chandelier Exit (Short, 3 ATRs) 0.44
    Upper Bollinger Bands 0.34
    Lower Bollinger Band 0.24
    Percent B (%b) 0.55
    BandWidth 34.51
    MACD Line -0.25
    MACD Signal Line -0.35
    MACD Histogram 0.0982
    Fundamentals Value
    Market Cap 15.61 Million
    Num Shares 52.6 Million
    EPS -1.40
    Price-to-Earnings (P/E) Ratio -0.21
    Price-to-Sales 178.41
    Price-to-Book 3.04
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.35
    Resistance 3 (R3) 0.35 0.33 0.34
    Resistance 2 (R2) 0.33 0.31 0.33 0.34
    Resistance 1 (R1) 0.31 0.31 0.32 0.31 0.33
    Pivot Point 0.29 0.29 0.30 0.29 0.29
    Support 1 (S1) 0.28 0.28 0.28 0.28 0.26
    Support 2 (S2) 0.26 0.27 0.26 0.26
    Support 3 (S3) 0.24 0.26 0.25
    Support 4 (S4) 0.24